ストックスクリーナーアプリを入手
0.85
3.13%
0.0258
アフターアワーズ：
.83
-0.02
-2.35%
前日終値:
$0.8242
開ける：
$0.8242
24時間の取引高:
996.34K
Relative Volume:
1.64
時価総額：
$73.69M
収益：
$2.24M
当期純損益:
$-136.67M
株価収益率:
-0.3712
EPS:
-2.29
ネットキャッシュフロー:
$-102.08M
1週間 パフォーマンス:
-6.60%
1か月 パフォーマンス:
-15.00%
6か月 パフォーマンス:
-62.72%
1年 パフォーマンス:
-80.55%
1日の値動き範囲:
$0.7811
$0.8898
1週間の範囲:
$0.7811
$0.937
52週間の値動き範囲:
$0.7811
$5.51
Century Therapeutics Inc Stock (IPSC) Company Profile
名前
Century Therapeutics Inc
セクター
電話
215-981-4000
住所
25 N 38TH STREET, 11TH FLOOR, PHILADELPHIA
IPSC を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IPSC
Century Therapeutics Inc
|
0.85 | 73.69M | 2.24M | -136.67M | -102.08M | -2.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 113.67B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 74.97B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.50B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 29.63B | 3.30B | -501.07M | 1.03B | -2.1146 |
Century Therapeutics Inc Stock (IPSC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-08-08 | 開始されました | Rodman & Renshaw | Buy |
| 2023-08-28 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2022-12-27 | 開始されました | Chardan Capital Markets | Buy |
| 2022-10-31 | 開始されました | Guggenheim | Buy |
| 2022-10-10 | 開始されました | Canaccord Genuity | Buy |
| 2022-05-23 | 開始されました | H.C. Wainwright | Buy |
| 2022-05-12 | 開始されました | William Blair | Mkt Perform |
| 2021-07-13 | 開始されました | BofA Securities | Buy |
| 2021-07-13 | 開始されました | JP Morgan | Overweight |
| 2021-07-13 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Century Therapeutics Inc (IPSC) 最新ニュース
Century Therapeutics, Inc. (NASDAQ:IPSC) Receives $10.00 Consensus PT from Brokerages - Defense World
Barclays PLC Increases Stock Position in Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
Century Therapeutics Partners with Experts for New Trial on Autoimmune Diseases - MyChesCo
Brokerages Set Century Therapeutics, Inc. (NASDAQ:IPSC) Price Target at $10.00 - MarketBeat
Century Therapeutics (NASDAQ:IPSC) Receives "Buy" Rating from Guggenheim - MarketBeat
HC Wainwright Reiterates Buy Rating for Century Therapeutics (NASDAQ:IPSC) - MarketBeat
Century Therapeutics launches cell therapy trial for autoimmune diseases - MSN
4 Analysts Have This To Say About Century Therapeutics - Benzinga
Century Therapeutics Announces Investigator-Initiated Phase - GlobeNewswire
Century Therapeutics Pioneers First iPSC-Derived NK Cell Therapy Trial for Autoimmune Diseases - StockTitan
Layoff Tracker: Notch Therapeutics to ‘Significantly Reduce’ Workforce - BioSpace
Century Therapeutics, Inc. (NASDAQ:IPSC) Short Interest Up 14.0% in December - Defense World
Short Interest in Century Therapeutics, Inc. (NASDAQ:IPSC) Increases By 14.0% - MarketBeat
Jane Street Group LLC Sells 62,588 Shares of Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
JPMorgan Chase & Co. Boosts Stake in Costamare Inc. (NYSE:CMRE) - Defense World
Century Therapeutics Unveils Advances in Cell Therapies - TipRanks
Geode Capital Management LLC Raises Stake in Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World
Geode Capital Management LLC Purchases 32,614 Shares of Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
Pre-market Movers: SANA, SLDB, JSPR, DRIO... - RTTNews
Century Therapeutics, Inc. (NASDAQ:IPSC) Shares Purchased by State Street Corp - Defense World
Pre-market Movers: ONCO, COEP, NUVB, SPRC... - RTTNews
Short Interest in Century Therapeutics, Inc. (NASDAQ:IPSC) Declines By 5.6% - MarketBeat
Century Therapeutics (NASDAQ:IPSC) Given New $4.00 Price Target at Piper Sandler - Defense World
Piper Sandler supports Century shares with Overweight rating as CAR-iNK study progresses - Investing.com UK
Century Therapeutics Inc receives Investment Bank Analyst Rating Update By Investing.com - Investing.com Nigeria
Charles Schwab Investment Management Inc. Sells 43,049 Shares of Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
Deal Watch: Merck Decides Better Late Than Never In GLP-1 Deal With Hansoh - Citeline News & Insights
Philadelphia cell therapy developer loses Big Pharma partnership valued at over $3B - The Business Journals
BMS’ Cost-Cutting Campaign Claims Collabs With Immatics, Century - BioSpace
Century Therapeutics ends collaboration with Bristol-Myers Squibb - Investing.com
Century Therapeutics ends collaboration with Bristol-Myers Squibb By Investing.com - Investing.com Australia
Fmr LLC Sells 428,768 Shares of Century Therapeutics, Inc. (NASDAQ:IPSC) - MarketBeat
Fmr LLC Cuts Stake in Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
Century Therapeutics Faces Termination of BMS Agreement - TipRanks
Century Therapeutics (NASDAQ:IPSC) Trading Down 4.3%Here's Why - MarketBeat
Shelby Keating Brown Obituary (2024)Jenkintown, PAJoseph J. McGoldrick Funeral Home, Inc.Jenkintown - Legacy.com
Likelihood of Approval and Phase Transition Success Rate ModelCNTY-101 in Systemic Lupus Erythematosus - GlobalData
Aclaris Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference - MyChesCo
Century Therapeutics to Present at Piper Sandler 36th Annual Healthcare Conference - MyChesCo
Follicular Lymphoma Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Malaysian Reserve
Casdin Capital, LLC Increases Stake in Century Therapeutics Inc - GuruFocus.com
Comparing Century Therapeutics (NASDAQ:IPSC) & Prime Medicine (NYSE:PRME) - Defense World
Benitec Biopharma to Participate in Upcoming Investor Conferences in December - The Manila Times
Century Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference - GlobeNewswire
Century Therapeutics Inc (IPSC) 財務データ
収益
当期純利益
現金流量
EPS
5.49%
0.79%
大文字化:
|
ボリューム (24 時間):